Zhejiang Hisun Pharma Files for US Approval to Start Clinical Trial of Statin
Zhejiang Hisun Pharmaceutical, a China company with numerous cross-border relationships, has successfully filed an Investigational New Drug application with the FDA in the US to begin clinical trials of an innovative cholesterol-lowering statin. Frontage Labs, a, CRO with operations in China and the US, completed the work on behalf of Hisun. Earlier this year, Hisun announced a $545 million generic drug JV with Pfizer. More details.... Stock Symbols:  (SHA: 600267)  (NYSE: PFE) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here